Furthermore, we have identified kinases and transcriptional regulators that can act as an entry point for targeted drug-screening strategies, and moreover, have found in pathogenic PD-neurons carrying the p.A30P SNCA mutation, upregulation of the alpha-synuclein interacting protein and early-stage PD biomarker BRSK1. Further validation studies will be required yet the exciting possibility of early-stage PD biomarkers can exert a profound clinical impact on the treatment of PD patients with potential treatment in the prodromal stage of the disease. This evidence concerns the gene BRSK1 and Parkinson disease.